Science Current Events | Science News | Brightsurf.com
 

Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management

May 03, 2012
Presentations at the 4th IMPAKT Breast Cancer Conference

American and Spanish researchers have found potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests, as they report at the 4th IMPAKT Breast Cancer Conference.

Because breast cancer is a biologically and clinically varied disease, doctors aim to choose appropriate treatments based on the characteristics of each patient's individual tumor. In the past, this has been done using pathology-based biomarkers; however these do not capture the full diversity of cancers.

"In this context, tests based on multi-gene expression have been shown to provide valuable information beyond the pathology-based biomarkers," says Dr Aleix Prat from the University of North Carolina, Chapel Hill. "However, multi-gene tests are not readily available in most of the world due to cost, assay turnaround times and other logistic issues."

Dr Prat and colleagues addressed this problem by trying to improve the current pathology-based biomarkers to better represent data coming from a particular multi-gene test known as the PAM50 breast cancer intrinsic classifier.

"The PAM50 breast cancer intrinsic classifier identifies two major groups of hormonal receptor-positive breast cancer known as the Luminal A and Luminal B subtypes. These two molecular entities have different risks of relapse and responses to chemotherapy," Dr Prat said.

Alongside the development of this multi-gene assay, clinicians have devised pathology-based surrogate assays for the identification of both the Luminal A and Luminal B subtypes. "In the absence of multi-gene assays, the pathology-based assays are clinically valuable," Dr Prat explained. "However, we observed that the current pathology-based definitions of the Luminal A and Luminal B subtypes still show a 30-40% discordance rate compared to multi-gene tests such as the PAM50 breast cancer intrinsic classifier."

The researchers examined differences in gene expression patterns between Luminal A and Luminal B tumors using the PAM50 test. They also collected clinical-pathological features from 2,950 primary tumors across four independent studies. Using statistical methods, they tested the independent prognostic significance of those features.

They found that the expression of progesterone receptor was one of the most discriminatory molecules. "Addition of quantitative scoring of the progesterone receptor into the current pathology-based Luminal A definition appears to better identify the subgroup of patients that have an outstanding survival when treated with endocrine therapy alone, and therefore do not need systemic chemotherapy," Dr Prat said. "This subpopulation of patients is likely to represent around 30% of the patients with low-risk pathology-defined Luminal A tumors."

"Current pathology-based definitions of the Luminal A and Luminal B subtypes are valuable, but can be improved for the management of hormonal receptor-positive breast cancer," the researcher concluded. "We believe that we have an improvement based upon the progesterone receptor, and given that progesterone receptor is widely used, our improvement could be widely and quickly adopted, if further validated."

According to Dr Di Leo, Hospital of Prato, Italy, former IMPAKT Chair, this is an important study with practical implications, because it tells us that the evaluation of the progesterone receptor along with the evaluation of other biomarkers, such as the estrogen receptor, proliferation markers and c-erbB2, may be relevant to better define the biological profile of the tumor. "This is a critical step towards a personalized medicine approach in breast cancer. It will be important to test the progesterone receptors according to a standardized approach across the pathology departments. One potential concern, in fact, could be the use of different techniques for the progesterone receptors evaluation, which might lead to discordant results between different pathology labs."

European Society for Medical Oncology


Related Breast Cancer Current Events and Breast Cancer News Articles


Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

New discovery approach accelerates identification of potential cancer treatments
Researchers at the University of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.

Decision analysis can help women make choices about breast reconstruction
Decision analysis techniques can help surgeons and patients evaluate alternatives for breast reconstruction-leading to a "good decision" that reflects the woman's preferences and values.

Cancer during pregnancy: Chemotherapy and radiotherapy are safe for babies, studies show
Children who are exposed to chemotherapy or radiotherapy while in the womb suffer no negative impacts on mental or cardiac development, international studies presented at the ESMO 2014 Congress in Madrid have shown.

Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

Many patients lack information about the use of targeted therapies, oncologists say
More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain.

Scientists discover a new role for estrogen in the pathology of breast cancer
Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs.

How the ends of chromosomes are maintained for cancer cell immortality
Maintaining the ends of chromosomes, called telomeres, is a requisite feature of cells that are able to continuously divide and also a hallmark of human cancer.

Discrepancies in access to new cancer drugs revealed
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain.

Skirt size increase linked to 33 percent greater postmenopausal breast cancer risk
Overall weight gain during adulthood is known to be a risk factor for breast cancer, but a thickening waist seems to be particularly harmful, indicating the importance of staving off a midriff bulge, the research shows.
More Breast Cancer Current Events and Breast Cancer News Articles

Let Me Get This Off My Chest: A Breast Cancer Survivor Over-Shares

Let Me Get This Off My Chest: A Breast Cancer Survivor Over-Shares
by Margaret Lesh (Author)


Tamoxifen hot flashes, mastectomy, reconstruction, breast cancer etiquette, Frankenboobs, bras with special attachments—Margaret Lesh shares all in her funny, heartfelt collection of essays, anecdotes, and life lessons from the perspective of a two-time breast cancer survivor. She’ll tell you when it’s okay to play the cancer card, what you should take to the hospital, and gives suggestions on how to cope in those dark moments of the soul. With practical tips sprinkled throughout, LET ME GET THIS OFF MY CHEST explores how breast cancer changed her outlook on life, offering honest insights, humor, and sensitivity as she looks for the silver lining in a not-so-great situation. Whether you are a woman diagnosed with breast cancer or whether you know someone with breast cancer, this...

The Breast Cancer Survival Manual, Fifth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer

The Breast Cancer Survival Manual, Fifth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer
by John Link (Author)


The updated edition of the essential resource for the 250,000 women diagnosed with breast cancer each yearBreast cancer is the leading cause of death in women from thirty-five to fifty-four years of age, and few things are as terrifying and confusing as a diagnosis of this disease. The fifth edition of The Breast Cancer Survival Manual is a concise, information-packed guide that is newly revised to contain all of the latest findings to help the woman facing treatment feel informed and empowered. John Link, M.D., a pioneer developer of Breastlink Medical Group in Southern California includes the most current medical advice on     • Tamoxifen, Herceptin, and other chemotherapy options      • The growing importance of HER2 oncogene testing      • Clinical research trials...

An Inconvenient Year

An Inconvenient Year
by Original Writing


It is a book that deals with the social side of cancer, as a parent, a lover and a friend. It is a story of coping with uncertainty, the reactions of others and living with them too. It documents the total shock and utter fear that a diagnosis brings and the hopelessness of surrendering to a treatment that brings its own baggage yet ultimately insures life. It talks about confronting hair loss along with discovering the more covert assault on all things feminine. Yet at the very root of the book, ahead of the fear and anger, there is humour and laughter. Though the story of cancer has been told before, it has not been told like this"

Fight Now: Eat & Live Proactively Against Breast Cancer

Fight Now: Eat & Live Proactively Against Breast Cancer
by Aaron Tabor, MD


Dr. Tabor’s FIGHT NOW book provides information on lifestyle choices that might improve breast health and overall health. The purpose of Dr. Tabor’s medical research is to empower you to become proactive against breast cancer now with specific food and lifestyle choices. We can make specific food and lifestyle choices to lower the risk of getting breast cancer, risk of recurrence, and risk of dying from breast cancer. The only alternative is to be reactive after you get breast cancer or have a recurrence of breast cancer. The choice is clear

Whether you are currently fighting breast cancer; are a survivor; or, simply trying to lower your risk, Dr. Tabor’s FIGHT NOW book will give you concise, critical information that you can start using today. You don’t have to read...

The Mayo Clinic Breast Cancer Book

The Mayo Clinic Breast Cancer Book
by By the breast-health experts at Mayo Clinic Cancer Center (Author)




Uplift: Secrets from the Sisterhood of Breast Cancer Survivors

Uplift: Secrets from the Sisterhood of Breast Cancer Survivors
by Barbara Delinsky (Author)


Barbara Delinsky's 1998 bestseller, COAST ROAD, featured a heroine who was a breast cancer survivor. To this day, it is the book that generates more mail than any of her others. That fact, combined with Barbara's ongoing commitment to breast cancer research, led her to her first book of nonfiction. Not a medical book -- there is no discussion of the pros and cons of a particular treatment or hospital or doctor -- UPLIFT is rather a collection of hundreds of pieces of practical and inspiring tidbits collected from survivors and their on everything from what kind of deodorant to use during radiation treatment to the best kinds of exercise aftloved ones. Think of it as "The Girlfriends' Guide" to breast cancer, with hints on everything from what kind of deodorant to use during radiation...

Breast Cancer (2014): 150 Latest & Illustrated Questions & Answers

Breast Cancer (2014): 150 Latest & Illustrated Questions & Answers


Why this book -- what is so exciting in the field of breast cancer? Take a look:* Many early breast cancers, with timely and appropriate treatments, are now curable.* The five-year survival rate of cancers confined to the milk ducts and milk lobules (DCIS & LCIS) has gone up to 100%.
*For the first time FDA labels a promising & new breast cancer drug the title of "Breakthrough" drug which doubles Progression Free Survival and extends overall survival (Ch:13).* The five-year survival of Stage 1 (larger tumor or lymph node-positive tumor) has gone up to almost 90%.* During the past 60 years, regardless of how advanced the breast cancer is, the average number of women who survive for 10 years has increased by 300%. And about 90% of women diagnosed with breast cancer will survive at...

Just Get Me Through This! - Revised and Updated

Just Get Me Through This! - Revised and Updated
by Deborah A. Cohen (Author), Robert M. Gelfand M.D. (Author)


Warm, reassuring, and practical advice for surviving breast cancer -- from someone who was there.

Surviving Triple-Negative Breast Cancer: Hope, Treatment, and Recovery

Surviving Triple-Negative Breast Cancer: Hope, Treatment, and Recovery
by Patricia Prijatel (Author), Carol Scott-Connor (Foreword)


After her diagnosis of hormone-negative breast cancer, health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, how it's treated, and how to keep it from recurring. While she learned that important research on triple-negative breast cancer (TNBC) was emerging, she found a noticeable lack of resources on the disease, which differs from hormone-positive breast cancer in important ways, including prognosis and treatment options. Triple-negative breast cancer disproportionately affects younger women and African-American women--and some forms of it can be more dangerous than other types of breast cancer. But there are many reasons to be hopeful, as Prijatel shows in this book.

Surviving Triple-Negative Breast Cancer delivers...

Breast Cancer Husband: How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond

Breast Cancer Husband: How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond
by Marc Silver (Author)


A unique guide, like none other on the market-packed with medical information, practical tips, psychological insight, and coping strategies-to help men help the women they love through this trying time.

When Marc Silver became a breast cancer husband three years ago, he learned firsthand how frightened and helpless the breast cancer husband feels. He searched in vain for a book that would give him the information and advice he so desperately sought. Now this award-winning journalist has compiled just the kind of emotionally supportive and useful resource that he wished he had been able to consult-to give men the tools they need to help their wives, their families, and themselves through this scary, uncertain time.

In his years as a consumer journalist and veteran of the News...

© 2014 BrightSurf.com